Piramal Pharma Solutions Opens Production Complex in Riverview, Michigan
06/21/2019
The total investment required for the expansion is approximately $10 million. This includes the new QC/analytical lab and two kilo-labs, as well as a doubling of the office space, which was needed to support the dramatic growth at the Riverview site.
To date, the Riverview site has had the containment capability and engineering controls to safely handle HPAPIs with OELs down to 1mcg/m3, at scales ranging from grams to ~250 kilos. The new wing, which consists of two kilo-labs and a QC/analytical lab, brings more to the table. It was designed with the required engineering controls and containment solutions to handle HPAPIs with OELs <1mcg/m3 and as low as ~20ng/m3. Materials will primarily be produced in this new wing at kilo-lab scales; lots of <5 kilos can be produced in this new state-of-the-art facility.
Vivek Sharma, CEO, Piramal Pharma Solutions, said, "We are one of only a few companies in the contract development and manufacturing market that have the capability to produce HPAPIs at such low OELs. It's another example of how we remain committed to partnering with our customers to serve the patient community and reduce the burden of disease."
According to company officials, historically the site operated as one shift, five days a week. Today, the site operates twelve hours a day, seven days a week, and is headed towards being a full 24/7 site. The Riverview site expansion also provides significant benefits to the local economy, including the addition of new high-tech jobs. The local staff has increased from 80 to 127 people, with a projected total of approximately 150 employees in the near future. This includes high-tech staffing of PhD and BS degred scientists, plus manufacturing operators and other skilled workers.
Vince Ammoscato, Vice President and Riverview Site Head, added, "This new, enhanced capability opens the site up to a new base of customers, including the antibody drug conjugate (ADC) market. We are equipped to offer ADC customers a seamless end-to-end solution, since we can develop the HPAPI payloads and linkers here in Riverview, send them to our site in Scotland for the antibody conjugation, then back to our Lexington, Kentucky site for sterile fill and finish."
The ability to offer a fully integrated solution for the ADC market, from proof-of-concept studies to conjugation development, clinical and commercial ADC GMP batch manufacturing and fill/finish, represents a significant strategic advantage for Piramal Pharma Solutions.
According to Mr. Ammoscato, more expansions are forthcoming. There is additional real estate available on the site for added capacity and new capability enhancements that will be designed to match the market needs of the pharmaceutical industry.
Project Announcements
Wyandot Snacks Expands Marion, Ohio, Production Operations
08/29/2025
Trane Technologies Expands Fort Smith, Arkansas, Operations
08/29/2025
BioMADE Plans Boone, Iowa, Bioindustrial Manufacturing Operations
08/29/2025
Choice Fabricators Expands Rainbow City, Alabama, Production Operations
08/29/2025
Ranovus Expands Ottawa, Ontario, Semiconductor Operations
08/29/2025
Belgium-Based Stow Group Plans Gordon County, Georgia, Manufacturing Operations
08/28/2025
Most Read
-
Tariffs, Talent, and U.S. Expansion
Q3 2025
-
What We’re Getting Wrong About Gen Z’s Future in the Skilled Trades
Q3 2025
-
Data Center Demand Stabilizes Amid Changing Market Forces
Q3 2025
-
A New Course for U.S. Shipbuilding
Q3 2025
-
Optimizing Your Rail-Served Transportation Network: Strategy Before Steel
Q2 2025
-
In Focus: AI Is Changing Incentives Math
Q2 2025
-
Rewriting the Rules of Warehouse ROI
Q3 2025